You are here

A Dose Escalation Study of PF‑06939999 in Participants With Advanced or Metastatic Solid Tumors.

Last updated on August 9, 2019

FOR MORE INFORMATION
Study Location
Henry-Joyce Cancer Clinic
Nashville, Tennessee, 37232 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Advanced Solid Tumors, Metastatic Solid Tumors
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Participants who are intolerant or resistant to standard treatment for selected solid
tumors

- At least one measurable lesion as defined by RECIST version 1.1

- ECOG Performance Status 0 or 1

- Adequate Bone Marrow Function

- Adequate Renal Function

- Adequate Liver Function

- Resolved acute effects of any prior therapy

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Known active uncontrolled or symptomatic CNS metastases.

- Major surgery, radiation therapy, systemic anti-cancer therapy or investigational
drug(s) within 4 weeks prior to study entry.

- Active, uncontrolled infection

- Known or suspected hypersensitivity to PF-06939999

- Inability to consume or absorb study drug

NCT03854227
Pfizer
Recruiting
A Dose Escalation Study of PF‑06939999 in Participants With Advanced or Metastatic Solid Tumors.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Locally Advanced or Metastatic Solid Tumors, BRCA 1 Genes
NCT03565991
All Genders
18+
Years
Multiple Sites
Advanced Solid Tumors, Metastatic Solid Tumors
NCT03854227
All Genders
18+
Years
Multiple Sites
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
NCT03330405
All Genders
18+
Years
Multiple Sites
Advanced Solid Tumors
NCT02997176
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now